

**Oxytocin Special Interest Group (OxytocinSIG) Charter**

**Introduction:**

Oxytocin is used for various indications during labor and delivery. Improper use and administration of oxytocin has led to fetal hypoxia, maternal morbidity and in some cases, maternal, fetal and neonatal deaths. Both ISMP Canada and ISMP USA have analyzed errors related to oxytocin and identified opportunities to improve the safe use of this high-alert medication in 2019 and 2020 respectively. In addition, safeguarding the use of oxytocin has been identified as a new Targeted Medication Safety Best Practices for Hospitals by ISMP USA in 2022. Thus, the IMSN executive committee has proposed that IMSN develop the IMSN Oxytocin Safety Interest Group to further address the safe use of oxytocin globally.

**Mandates:**

1. To share issues and errors on use and administration of oxytocin among members
	1. Include various types of issues that lead to errors and fetal hypoxia
	2. Include errors due to mix up with other medications
	3. Include errors related to delivery devices
	4. Evaluate errors in the context of indications for use
2. To develop comprehensive and global applicable recommendations including a guidance document on safe use of oxytocin
3. To engage international partners including ISoP, UMC and WHO to facilitate implementation of recommendations

The findings and recommendations will be made publicly available in a specific section of the IMSN website.

**Membership**

The Oxytocin Special Interest Group is chaired by Rita K. Jew, President of ISMP. The Group will consists of IMSN members on a voluntary basis. The IMSN Chair and the General Secretary will provide input and suggestions as needed.

It is expected the membership will also include patient safety, pharmacovigilance centres, as well as regulatory agencies. Other key stakeholders including WHO, UMC, ISoP and others will be invited.

**Organization and Communication**

Communication and information will be shared among members of the Interest Group in the IMSN website under

[https://www.intmedsafe.net/forums/forum/oxytocin-project-special-interest-group/](https://can01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.intmedsafe.net%2Fforums%2Fforum%2Foxytocin-project-special-interest-group%2F&data=04%7C01%7C%7Cf59318cfa2db4805470908d9da8a05a0%7C4e1b261fb7fc4b3eb7107b9f26f3130a%7C0%7C0%7C637781108595804533%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=qWDK29I2I3kig8SZ2SJKXjjRqvnv8Up5tE3eshIaiMo%3D&reserved=0)

The meeting format will be on-line (Zoom or conference call)

Expected timeline: the duration of 2022